SEC Tracker
Get the app

vTv Therapeutics VTVT

vTv Therapeutics FY 2022: revenue $2.0M, down 50%

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers vTv Therapeutics reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$2.0M−50% from $4.0M in FY 202110-K income statement, on EDGAR
  2. Net income−$19.2MAgainst −$13.0M in FY 202110-K income statement, on EDGAR
  3. Cash and cash equivalents$12.1M−10% from $13.4M in FY 202110-K balance sheet, on EDGAR
  4. Cash from operations−$16.0MAgainst −$19.3M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when vTv Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ovid Therapeutics OVID public float $22M, Jun 30, 2025
  2. Marimed MRMD public float $23M, Jun 30, 2025
  3. Aptose Biosciences APTOF public float $22M, Jun 28, 2025
  4. Dare Bioscience DARE public float $21M, Jun 30, 2025
  5. Lunai Bioworks LNAI public float $21M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.